Human Drug Compounding Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act
Revision of a currently approved collection
No
Regular
Approved without change
11/25/2022
10/25/2022
table that charts list comparision
Inventory as of this Action
Requested
Previously Approved
11/30/2025
36 Months From Approved
10/31/2023
17,191
0
9,080
8,944
0
8,730
0
0
0
This information collection supports implementation of Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act (FD&C Act) - which governs pharmacy compounding and outsourcing facilities. The requirements include reporting, recordkeeping, and disclosures.
To account for revising the information collection to include registration of outsourcing facilities and reporting of drugs, we have adjusted the estimated burden by an increase of 8,111 responses and 214 hours annually. Upon OMB approval we intend to discontinue control no. 0910-0827.
On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control number;
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.